NOVEN ANNOUNCES FDA ADVISORY COMMITTEE VOTE ON INVESTIGATIONAL LOW-DOSE MESYLATE SALT OF PAROXETINE (LDMP) FOR VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE (Noven Pharmaceuticals Inc)

(Source: Noven Pharmaceuticals Inc) NOVEN ANNOUNCES FDA ADVISORY COMMITTEE VOTE ON INVESTIGATIONAL LOW-DOSE MESYLATE SALT OF PAROXETINE (LDMP) FOR VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE Miami, FL and New York, NY, March 4, 2013 -- Noven Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) Reproductive Health Drugs Advisory Committee voted 10 to 4 that the overall risk/benefit profile of low-dose mesylate salt of paroxetine (LDMP; 7.5 mg/day) is not acceptable to support approval. LDMP is an...